Barclays’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
Sell
-594,900
Closed -$14.3M 8066
2014
Q2
$14.3M Buy
594,900
+585,800
+6,437% +$6.11M 0.02% 916
2014
Q1
$55K Buy
+9,100
New +$63.5K ﹤0.01% 5925
2013
Q4
Sell
-3,000
Closed -$15K 7870
2013
Q3
$15K Sell
3,000
-9,200
-75% -$40.3K ﹤0.01% 6658
2013
Q2
$44K Buy
+12,200
New +$49.9K ﹤0.01% 6398

Barclays's IDIX Position: Q3 2014 in Review

Barclays sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q3 2014, closing a stake of 1,402,950 shares — an estimated $33.7M sold.

Barclays first reported a position in IDIX in Q2 2013 and held it in 5 quarters. The position peaked at $33.7M in Q2 2014. 0 funds tracked by Wall St. Rank hold IDIX as of Q3 2014.

  • Barclays reported no remaining IDENIX PHARMACEUTICALS INC position as of Q3 2014 after selling out during the quarter.
  • Barclays sold 1,402,950 IDENIX PHARMACEUTICALS INC shares in Q3 2014, an estimated $33.7M.
  • Barclays first reported a position in IDENIX PHARMACEUTICALS INC in Q2 2013 and held it in 5 quarters.
  • Barclays's IDENIX PHARMACEUTICALS INC position peaked at $33.7M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q3 2014.

Based on Barclays's 13F filing for Q3 2014, filed 14 Nov 2014.